Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 12/2015

01-11-2015 | Original Article

Basal 18 F-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography as a prognostic biomarker in patients with locally advanced breast cancer

Authors: Ana María García Vicente, Ángel Soriano Castrejón, Jesús Fernando López-Fidalgo, Mariano Amo-Salas, María del Mar Muñoz Sanchez, Ruth Álvarez Cabellos, Ruth Espinosa Aunión

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 12/2015

Login to get access

Abstract

Aim

To explore the relationship between basal 18 F-FDG PET/CT information in breast tumours and survival in locally advanced breast cancer (LABC).

Methods

This prospective, multicentre study included 198 women diagnosed with LABC. All patients underwent 18 F-FDG PET/CT prior to treatment. The maximum standardized uptake value (SUVmax) in tumor (T), lymph nodes (N) and the N/T ratio was obtained in all cases. Stage according to PET/CT imaging (metabolic stage) and conventional imaging techniques (clinical stage) was established. During follow-up, patient status was established (disease free status or not). The relationship between all the variables and overall survival (OS) and disease-free survival (DFS) was analysed using the Kaplan-Meier and Cox regression methods. A ROC analysis was performed to obtain a cut-off value of SUVmax that was useful in the prediction of outcome.

Results

The mean SUVmax ± SD values in the primary tumour, lymph nodes and the SUVmax N/T index were 7.40 ± 5.57, 4.17 ± 4.74 and 0.73 ± 1.20, respectively. Higher semiquantitative metabolic values were found in more advanced metabolic and clinical stages. During follow-up, 78.4 % of patients were free of disease. Significant relationships were observed between SUVT and SUVN and patient status. With respect to OS and DFS, significant differences were detected for the metabolic stage. Kaplan-Meier analysis revealed that using the cut-off values, a primary-tumour SUVmax ≥ 6.05 or a nodal SUVmax ≥2.25 were significantly correlated with DFS and OS.

Conclusion

PET imaging with 18 F-FDG offers prognostic information for LABC that can be obtained preoperatively and noninvasively
Literature
1.
Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat. 1992;22:207–19.CrossRefPubMed
2.
Brown RS, Wahl RL. Overexpression of Glut-1 glucose transporter in human breast cancer. Cancer. 1993;72:2979–85.CrossRefPubMed
3.
Ueda S, Tsuda H, Asakawa H, Shigekawa T, Fukatsu K, Kondo N, et al. Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/ computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer. Jpn J Clin Oncol. 2008;38:250–8.CrossRefPubMed
4.
García Vicente AM, Soriano Castrejón A, Relea Calatayud F, Palomar Muñoz A, León Martín AA, Chacón López-Muñiz I, et al. 18F-FDG retention index and biologic prognostic parameters in breast cancer. Clin Nucl Med. 2012;37:460–6.CrossRefPubMed
5.
Dunnwald LK, Gralow JR, Ellis GK, Livingston RB, Linden HM, Specht JM, et al. Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol. 2008;26:4449–57.PubMedCentralCrossRefPubMed
6.
Oshida M, Uno K, Suzuki M, Nagashima T, Hashimoto H, Yagata H, et al. Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F]-D-glucose. Cancer. 1998;82:2227–34.CrossRefPubMed
7.
Inoue T, Yutani K, Taguchi T, Tamaki Y, Shiba E, Noguchi S. Preoperative evaluation of prognosis in breast cancer patients by [(18)F]2-Deoxy-2-fluoro-D-glucose-positron emission tomography. J Cancer Res Clin Oncol. 2004;130:273–8.CrossRefPubMed
8.
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ, et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22:1736–47.PubMedCentralCrossRefPubMed
9.
Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, et al. Comparison of Triple-negative and Estrogen Receptor positive/ Progesterone Receptor positive/HER2-negative Breast Carcinoma Using Quantitative Fluorine-18 Fluorodeoxyglucose/Positron Emission Tomography Imaging Parameters. A Potentially Useful Method for Disease Characterization. Cancer. 2008;112:995–1000.CrossRefPubMed
10.
Shimoda W, Hayashi M, Murakami K, Oyama T, Sunagawa M. The Relationship between FDG Uptake in PET Scans and Biological Behavior in Breast Cancer. Breast Cancer. 2007;14:260–8.CrossRefPubMed
11.
Song B-I, Hong C, Lee H, Kang S, Jeong SY, Kim HW, et al. Prognostic value of primary tumor uptake on F-18 FDG PET/CT in patients with invasive ductal breast cancer. Nucl Med Mol Imaging. 2011;45:117–24.PubMedCentralCrossRefPubMed
12.
O JH, Choi WH, Han EJ, Choi E-K, Chae BJ, Park Y-G, et al. The prognostic value of 18F-FDG PET/CT for early recurrence in operable breast cancer: comparison with TNM Stage. Nucl Med Mol Imaging. 2013;47:263–7.PubMedCentralCrossRefPubMed
13.
Groheux D, Giacchetti S, Delord M, de Roquancourt A, Merlet P, Hamy AS, et al. Prognostic impact of 18F-FDG PET/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer. Eur J Nucl Med Mol Imaging. 2015;42:377–85.CrossRefPubMed
14.
Hyun CL, Lee HE, Kim KS, Kim SW, Kim JH, Choe G, et al. The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer. J Clin Pathol. 2008;61:317–21.CrossRefPubMed
15.
Song B-I, Lee S-W, Jeong SY, Chae YS, Lee WK, Ahn B-C, et al. 18F-FDG uptake by metastatic axillary lymph nodes on pretreatment PET/CT as a prognostic factor for recurrence in patients with invasive ductal breast cancer. J Nucl Med. 2012;53:1337–44.CrossRefPubMed
16.
Chang C-C, Tu H-P, Chen Y-W, Lin C-Y, Hou M-F. Tumour and lymph node uptakes on dual-phased 2-deoxy-2-[18F]fluoro-D-glucose parameters in breast cancer positron emission tomography/computed tomography correlate with prognostic. J Inter Med Res. 2014;42:1209–21.CrossRef
17.
Lee AY, Choi SJ, Jung KP, Park JS, Lee SM, Bae SK. Characteristics of Metastatic Mediastinal Lymph Nodes of Non-Small Cell Lung Cancer on Preoperative F-18 FDG PET/CT. Nucl Med Mol Imaging. 2014;48:41–6.PubMedCentralCrossRefPubMed
18.
Koksal D, Demirag F, Bayiz H, Ozmen O, Tatci E, Berktas B, et al. The correlation of SUVmax with pathological characteristics of primary tumor and the value of Tumor/ Lymph node SUVmax ratio for predicting metastasis to lymph nodes in resected NSCLC patients. J Cardiothorac Surg. 2013;8:63.PubMedCentralCrossRefPubMed
19.
Cerfolio RJ, Bryant AS. Ratio of the maximum standardized uptake value on FDG-PET of the mediastinal (N2) lymph nodes to the primary tumor may be a universal predictor of nodal malignancy in patients with non-small cell lung cancer. Ann Thorac Surg. 2007;83:1826–30.CrossRefPubMed
20.
Humbert O, Berriolo-Riedinger A, Cochet A, Gauthier M, Charon-Barra C, Guiu S, et al. Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using 18F-FDG PET in luminal HER2-negative breast cancer. Eur J Nucl Med Mol Imaging. 2014;41:416–27.CrossRefPubMed
21.
Aogi K, Kadoya T, Sugawara Y, Kiyoto S, Shigematsu H, Masumoto N, et al. Utility of 18F FDG-PET/CT for predicting prognosis of luminal-type breast cancer. Breast Cancer Res Treat. 2015;150:209–17.PubMedCentralCrossRefPubMed
22.
Riedl CC, Slobod E, Jochelson M, Morrow M, Goldman DA, Gonen M, et al. Retrospective Analysis of 18F-FDG PET/CT for Staging Asymptomatic Breast Cancer Patients Younger Than 40 Years. J Nucl Med. 2014;55:1578–83.PubMedCentralCrossRefPubMed
23.
Cochet A, Dygai-Cochet I, Riedinger JM, Humbert O, Berriolo- Riedinger A, Toubeau M, et al. (18)F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations. Eur J Nucl Med Mol Imaging. 2014;41:428–37.CrossRefPubMed
24.
Groheux D, Hindié E, Delord M, Giacchetti S, Hamy AS, de Bazelaire C, et al. Prognostic impact of 18FDG-PET-CT findings in clinical stage III and IIB breast cancer. J Natl Cancer Inst. 2012;104:1879–87.PubMedCentralCrossRefPubMed
25.
Kim JY, Lee SH, Kim S, Kang T, Bae JT. Tumour 18 F-FDG uptake on preoperative PET/CT may predict axillary lymph node metastasis in ER-positive/HER2-negative and HER2-positive breast cancer subtypes. Eur Radiol. 2015;25:1172–81.CrossRefPubMed
26.
Ferguson NL, Bell J, Heidel R, Lee S, Vanmeter S, Duncan L, et al. Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women. Breast J. 2013;19:22–30.CrossRefPubMed
27.
Jatoi I, Hilsenbeck SG, Clark GM, Osborne CK. Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol. 1999;17:2334–40.PubMed
28.
García Vicente AM, Soriano Castrejón A, Cruz Mora MA, González Ageitos A, Muñoz Sánchez Mdel M, León Martín A, et al. Semiquantitative lymph node assessment of 18F-FDG PET/CT in locally advanced breast cancer: correlation with biological prognostic factors. Eur J Nucl Med Mol Imaging. 2013;40:72–9.CrossRefPubMed
Metadata
Title
Basal 18 F-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography as a prognostic biomarker in patients with locally advanced breast cancer
Authors
Ana María García Vicente
Ángel Soriano Castrejón
Jesús Fernando López-Fidalgo
Mariano Amo-Salas
María del Mar Muñoz Sanchez
Ruth Álvarez Cabellos
Ruth Espinosa Aunión
Publication date
01-11-2015
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 12/2015
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-015-3102-x

Other articles of this Issue 12/2015

European Journal of Nuclear Medicine and Molecular Imaging 12/2015 Go to the issue

Original Article

Chronotropic response to vasodilator-stress in patients submitted to myocardial perfusion imaging: impact on the accuracy in detecting coronary stenosis

Original Article

18F-FDG PET/CT following chemoradiation of uterine cervix cancer provides powerful prognostic stratification independent of HPV status: a prospective cohort of 105 women with mature survival data

UEMS\/EBNM

Nuclear medicine training and practice in Italy

Original Article

The value of SPECT/CT in carpal boss

Original Article

Evaluation of two novel 64Cu-labeled RGD peptide radiotracers for enhanced PET imaging of tumor integrin αvβ3

Original Article

Feasibility of one-eighth time gated myocardial perfusion SPECT functional imaging using IQ-SPECT